{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T09:08:36Z","timestamp":1778663316569,"version":"3.51.4"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T00:00:00Z","timestamp":1731369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["TTU-05-702"],"award-info":[{"award-number":["TTU-05-702"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["TTU-05-708"],"award-info":[{"award-number":["TTU-05-708"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["KR 2913\/2-1"],"award-info":[{"award-number":["KR 2913\/2-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["390874280"],"award-info":[{"award-number":["390874280"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["158989968"],"award-info":[{"award-number":["158989968"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.virol.2024.110280","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T15:36:01Z","timestamp":1730302561000},"page":"110280","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["MitoTempo treatment as an approach to cure persistent viral infections?"],"prefix":"10.1016","volume":"600","author":[{"given":"Jasmin","family":"Mischke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Cornberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9666-0753","authenticated-orcid":false,"given":"Anke R.M.","family":"Kraft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.virol.2024.110280_bib1","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.jhep.2019.06.025","article-title":"Elimination of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses","volume":"71","author":"Aregay","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.virol.2024.110280_bib2","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nature04444","article-title":"Restoring function in exhausted CD8 T cells during chronic viral infection","volume":"439","author":"Barber","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.virol.2024.110280_bib3","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3109\/02656736.2014.971446","article-title":"Reactive oxygen species, heat stress and oxidative-induced mitochondrial damage. A review","volume":"30","author":"Belhadj Slimen","year":"2014","journal-title":"Int. J. Hyperther."},{"key":"10.1016\/j.virol.2024.110280_bib4","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.immuni.2016.07.008","article-title":"Bioenergetic insufficiencies due to metabolic alterations regulated by the inhibitory receptor PD-1 are an early driver of CD8(+) T cell exhaustion","volume":"45","author":"Bengsch","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.virol.2024.110280_bib5","doi-asserted-by":"crossref","first-page":"10411","DOI":"10.1021\/acs.jmedchem.6b00669","article-title":"Development of therapeutics that induce mitochondrial biogenesis for the treatment of acute and chronic degenerative diseases","volume":"59","author":"Cameron","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.virol.2024.110280_bib6","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1159\/000485287","article-title":"Mitochondria-targeted antioxidant mito-tempo protects against aldosterone-induced renal injury in vivo","volume":"44","author":"Ding","year":"2017","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.virol.2024.110280_bib7","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s00204-016-1692-0","article-title":"Mitochondria-targeted antioxidant mito-tempo protects against acetaminophen hepatotoxicity","volume":"91","author":"Du","year":"2017","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.virol.2024.110280_bib8","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1053\/j.gastro.2009.09.052","article-title":"Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B","volume":"138","author":"Fisicaro","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.virol.2024.110280_bib9","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nm.4275","article-title":"Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B","volume":"23","author":"Fisicaro","year":"2017","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.virol.2024.110280_bib10","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jhep.2019.06.028","article-title":"Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: a pilot study","volume":"71","author":"Gane","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.virol.2024.110280_bib11","unstructured":"Gilead Sciences. Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB). Available online: https:\/\/ClinicalTrials.gov\/show\/NCT04891770."},{"key":"10.1016\/j.virol.2024.110280_bib12","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1159\/000446718","article-title":"Checkpoint blockade - a new treatment paradigm in renal cell carcinoma","volume":"39","author":"Gr\u00fcnwald","year":"2016","journal-title":"Oncol. Res. Treat."},{"key":"10.1016\/j.virol.2024.110280_bib13","first-page":"119","article-title":"Checkpoint inhibitors","volume":"116","author":"Heinzerling","year":"2019","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.virol.2024.110280_bib14","unstructured":"Janssen Research & Development, L. An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(T)Ide Analogs (NA), and a Programmed Cell Death Protein Receptor-1 (PD-1) Inhibitor in Chronic Hepatitis B Participants. Available online: https:\/\/ClinicalTrials.gov\/show\/NCT05275023."},{"key":"10.1016\/j.virol.2024.110280_bib15","doi-asserted-by":"crossref","first-page":"14733","DOI":"10.1073\/pnas.1009731107","article-title":"Cooperation of tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection","volume":"107","author":"Jin","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.virol.2024.110280_bib16","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.virol.2014.12.033","article-title":"T cell exhaustion during persistent viral infections","volume":"479\u2013480","author":"Kahan","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.virol.2024.110280_bib17","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1126\/science.aaf0683","article-title":"Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent","volume":"355","author":"Kamphorst","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.virol.2024.110280_bib18","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00795-20","article-title":"PD-L1 checkpoint inhibition narrows the antigen-specific T cell receptor repertoire in chronic lymphocytic choriomeningitis virus infection","volume":"94","author":"Klein","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2024.110280_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens12050716","article-title":"Individual epitope-specific CD8+ T cell immune responses are shaped differently during chronic viral infection","volume":"12","author":"Klein","year":"2023","journal-title":"Pathogens"},{"key":"10.1016\/j.virol.2024.110280_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/srep32683","article-title":"Therapeutically targeting mitochondrial redox signalling alleviates endothelial dysfunction in preeclampsia","volume":"6","author":"McCarthy","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.virol.2024.110280_bib21","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.3390\/v14102293","article-title":"Cross-reactive T cell response exists in chronic lymphocytic choriomeningitis virus infection upon pichinde virus challenge","volume":"14","author":"Mischke","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.virol.2024.110280_bib22","first-page":"44","article-title":"Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons","volume":"20","author":"Naimi","year":"2022","journal-title":"CCS"},{"key":"10.1016\/j.virol.2024.110280_bib23","unstructured":"PharmaEssentia. The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults with Chronic Hepatitis B Or D Infection. Available online: https:\/\/ClinicalTrials.gov\/show\/NCT04638439."},{"key":"10.1016\/j.virol.2024.110280_bib24","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.virol.2024.110280_bib25","first-page":"2123","article-title":"Phenotypic CD8 T cell profiling in chronic hepatitis B to predict HBV-specific CD8 T cell susceptibility to functional restoration in vitro. Gut","volume":"72","author":"Rossi","year":"2023"},{"key":"10.1016\/j.virol.2024.110280_bib26","first-page":"460","article-title":"Checkpoint inhibitors in lung cancer: latest developments and clinical potential","volume":"8","author":"Schvartsman","year":"2016","journal-title":"TAM"},{"key":"10.1016\/j.virol.2024.110280_bib27","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s40265-015-0442-6","article-title":"Nivolumab: a review in advanced melanoma","volume":"75","author":"Scott","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.virol.2024.110280_bib28","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.immuni.2012.10.020","article-title":"Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signaling","volume":"38","author":"Sena","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.virol.2024.110280_bib29","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.virol.2024.110280_bib30","first-page":"80","article-title":"T cell responses during HBV and HCV infections: similar but not quite the same?","volume":"51","author":"Shoukry","year":"2021","journal-title":"COVIRO"},{"key":"10.1016\/j.virol.2024.110280_bib31","unstructured":"The Second Affiliated Hospital of Chongqing Medical Universitya The Second Affiliated Hospital of Chongqing Medical University. A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (B). Available online: https:\/\/ClinicalTrials.gov\/show\/NCT05771402."},{"key":"10.1016\/j.virol.2024.110280_bib32","unstructured":"The Second Affiliated Hospital of Chongqing Medical University. A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (A). Available online: https:\/\/ClinicalTrials.gov\/show\/NCT05769816."},{"key":"10.1016\/j.virol.2024.110280_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.870156","article-title":"Therapeutic targeting of endosome and mitochondrial reactive oxygen species protects mice from influenza virus morbidity","volume":"13","author":"To","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.virol.2024.110280_bib34","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.freeradbiomed.2007.12.036","article-title":"A mitochondria-targeted nitroxide is reduced to its hydroxylamine by ubiquinol in mitochondria","volume":"44","author":"Trnka","year":"2008","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.virol.2024.110280_bib35","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cell.2009.06.036","article-title":"Redefining chronic viral infection","volume":"138","author":"Virgin","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.virol.2024.110280_bib36","article-title":"Lymphocytic choriomeningitis virus (LCMV): propagation, quantitation, and storage","volume":"15","author":"Welsh","year":"2008","journal-title":"Curr Protoc Microbiol"},{"key":"10.1016\/j.virol.2024.110280_bib37","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.virol.2024.110280_bib38","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.virol.2024.110280_bib39","doi-asserted-by":"crossref","first-page":"4911","DOI":"10.1128\/JVI.77.8.4911-4927.2003","article-title":"Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment","volume":"77","author":"Wherry","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2024.110280_bib40","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15050","article-title":"TCF1+ hepatitis C virus-specific CD8+ T cells are maintained after cessation of chronic antigen stimulation","volume":"8","author":"Wieland","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.virol.2024.110280_bib43","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aai8593","article-title":"The TCF1-bcl6 Axis counteracts type I interferon to repress exhaustion and maintain T cell stemness","volume":"1","author":"Wu","year":"2016","journal-title":"Sci Immunol"},{"key":"10.1016\/j.virol.2024.110280_bib44","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1111\/bph.13518","article-title":"Mitochondrial dysfunction in inflammatory responses and cellular senescence: pathogenesis and pharmacological targets for chronic lung diseases","volume":"173","author":"Yue","year":"2016","journal-title":"Br. J. Pharmacol."}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682224003040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682224003040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T08:13:05Z","timestamp":1778659985000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0042682224003040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":42,"alternative-id":["S0042682224003040"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2024.110280","relation":{},"ISSN":["0042-6822"],"issn-type":[{"value":"0042-6822","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MitoTempo treatment as an approach to cure persistent viral infections?","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2024.110280","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110280"}}